Neogenomics, Inc.
NEO
$16.05
$0.211.33%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 11.19% | 10.95% | 10.11% | 10.10% | 9.70% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 11.19% | 10.95% | 10.11% | 10.10% | 9.70% |
| Cost of Revenue | 11.07% | 13.34% | 11.60% | 10.36% | 7.37% |
| Gross Profit | 11.35% | 7.93% | 8.20% | 9.76% | 12.83% |
| SG&A Expenses | 1.05% | 6.35% | 8.07% | 9.76% | 8.74% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 6.45% | 9.94% | 10.32% | 10.42% | 8.68% |
| Operating Income | 33.23% | -0.62% | -12.29% | -13.27% | -0.80% |
| Income Before Tax | 48.27% | -29.93% | -36.68% | -42.79% | -26.39% |
| Income Tax Expenses | -89.02% | -180.43% | -15.08% | 75.20% | 71.12% |
| Earnings from Continuing Operations | 50.14% | -27.87% | -37.22% | -45.98% | -32.46% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 50.14% | -27.87% | -37.22% | -45.98% | -32.46% |
| EBIT | 33.23% | -0.62% | -12.29% | -13.27% | -0.80% |
| EBITDA | 198.75% | -927.46% | -1,587.56% | -1,538.28% | -27.02% |
| EPS Basic | 50.58% | -26.52% | -35.69% | -44.27% | -30.91% |
| Normalized Basic EPS | 28.96% | -10.14% | -22.92% | -23.71% | -2.98% |
| EPS Diluted | 50.61% | -25.88% | -35.02% | -43.55% | -29.92% |
| Normalized Diluted EPS | 29.07% | -10.14% | -22.92% | -23.71% | -2.98% |
| Average Basic Shares Outstanding | 1.26% | 1.24% | 1.14% | 1.09% | 1.05% |
| Average Diluted Shares Outstanding | 1.50% | 1.24% | 1.14% | 1.09% | 1.05% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |